Diosuxentan

Diosuxentan
Clinical data
Other names	SC-0062
Identifiers
	IUPAC name 5-(1,3-benzodioxol-5-yl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(2-methoxyethylsulfamoyl)pyrimidin-4-amine;
CAS Number	2305865-93-2;
PubChem CID	155097467;
IUPHAR/BPS	13748;
UNII	RJ4QU53ZY3;
Chemical and physical data
Formula	C20H21BrN6O7S
Molar mass	569.39 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC4=C(C=C3)OCO4;
	InChI InChI=InChI=1S/C20H21BrN6O7S/c1-30-5-4-26-35(28,29)27-18-17(13-2-3-15-16(8-13)34-12-33-15)19(25-11-24-18)31-6-7-32-20-22-9-14(21)10-23-20/h2-3,8-11,26H,4-7,12H2,1H3,(H,24,25,27); Key:CJPSPQBOXPPXMN-UHFFFAOYSA-N;

Diosuxentan is an investigational new drug that is being developed by Biocity Biopharmaceutics for the treatment of diabetic nephropathy. It is an endothelin A receptor antagonist.^[1]^[2]

References

↑ "Diosuxentan". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ Davenport A, Anwar M, Kuc R, Brynne L, Mercier A, Åstrand M, et al. (January 2026). "Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system". Canadian Journal of Physiology and Pharmacology. 104: 1–16. doi:10.1139/cjpp-2026-0068. PMID 42378327.